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osting by EAbstract The relationship of serum alanine aminotransferase (ALT) level and viral replication to
liver damage in chronic hepatitis C virus (HCV) patients remains unclear.
The aim of the present study was to determine whether the stage of ﬁbrosis correlates with HCV-
RNA titer and/or serum ALT level in patients with chronic hepatitis C (genotype 4) infection.
Clinical and biochemical characteristics were collected from 138 patients with chronic HCV geno-
type 4 infection. Quantitative HCV-RNA level measurement, HCV genotyping, and abdominal
ultrasonography were investigated in all patients.
Liver biopsywas done for 80 patients and the remaining 58 patientswere examined usingFibroscan.
Highly signiﬁcant higher percentage of cases with high level of HCV viremia was found among
patientswith ﬁbrosis stage 3 as compared to other stages of ﬁbrosis. In contrast, grades of activity were
independent of serum HCV-RNA titer.
Patients with stages 1 and 4 hepatic ﬁbrosis had signiﬁcantly higher levels ofALT than patients with
other stages of ﬁbrosis. In contrast, an insigniﬁcant correlation was found between ALT level and
grade of necroinﬂammation..com
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208 R. Al SwaffIn conclusion neither ALT level nor HCV viremia can reﬂect the histological liver change
accurately. As a result, liver biopsy or other noninvasive procedures that measure liver stiffness
(i.e., Fibroscan) remain essential for accurate staging of liver ﬁbrosis in patients with genotype 4
chronic HCV infection.
 2012 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Patients infected with hepatitis C virus (HCV) have different
clinical outcomes, ranging from acute resolving hepatitis to
chronic liver disease including liver cirrhosis or hepatocellular
carcinoma [1].
Egypt has the highest prevalence of HCV worldwide (15%)
[2] and the highest prevalence of HCV-4, which are responsible
for almost 90% of HCV infections [3].
Because the relationship of serumALT (alanine aminotrans-
ferase) level to liver damage or viral replication in chronic
HCV carriers remains unclear, liver biopsy is essential to evalu-
ate the degree of liver damage in these subjects. However, it is
practically difﬁcult to perform liver biopsy in all asymptomatic
healthy carriers with normal ALT level [4,5] and therefore, a
noninvasive approach is required to make an accurate
diagnosis.
Transient elastography (TE) using FibroScan is a new, non-
invasive, and reproducible technique that evaluates tissue
stiffness. Liver stiffness measurement (LSM) has been demon-
strated to be a reliable tool for assessing the hepatic ﬁbrosis,
mainly in patients with chronic hepatitis. Because TE can be
performed rapidly, painlessly, and has high patient acceptance,
it is likely to become a common way of assessing ﬁbrosis in rou-
tine practice [6].
Studies on the correlations between HCV-RNA titers or
HCV genotype, and the severity of liver damage have shown
conﬂicting results [7–11]. In addition, whether HCV-RNA titer
is a better predictor of underlying liver injury than serum ALT
is not known.
The aim of the present study was to determine whether the
stage of ﬁbrosis correlates with HCV-RNA titer and/or serum
ALT level in patients with chronic hepatitis C (genotype 4)
infection.
2. Methods
This study was conducted in the Gastroenterology and Hepa-
tology Unit, Department of Internal Medicine, Ain Shams
University Hospital; in the period between May 2009 and
August 2011. A total of 138 patients with chronic HCV (geno-
type 4) infection were enrolled in the study.
All patients were subjected to the following.
History taking, thorough clinical examination, calculation
of Body Mass Index (BMI), laboratory investigations includ-
ing: fasting and post prandial blood glucose level, liver func-
tion tests, a fetoprotein, prothrombin time and International
Neutralization Ratio (INR), renal function tests, complete
blood count, serum ceruloplasmin, ANA (Antinuclear Anti-
body), HIV and hepatitis C virus antibodies using ELISA tech-
nique, HBsAg, HBsAb, HBcAb, HBeAg and HBeAb.HCV RNA (PCR) in serum, both quantitative and
qualitative:
– Automated PCR (using Cobas Ammplicor HCVv2.0,
Roche molecular system) was used for qualitative HCV-
RNA detection.
– Manual PCR (using Cobas Ammplicor HCVv2.0, Roche
molecular system) was used for quantifying HCV RNA.
– Interpretation of viremia: <200.000 IU/ml: low viremia,
200.000–2000.000 IU/ml: moderate viremia,
>2000.000 IU/ml: high viremia.
HCV genotyping using INNO-LIPA HCVII test (INNO-
LiPAHCV II, Innogenetics, Ghent, Belgium). This test is based
on the reverse hybridization of 50 untranslated region PCR
ampliﬁcation product [12].
Abdominal ultrasonography (Aloka SSD620, Japan) using
3.5 MHz convex probe.
Fibroscan was done for 58 patients. Fibroscan is designed
for noninvasive assessment of liver ﬁbrosis and is based on
elastometry (or one dimensional transient elastography), hard-
er the tissue, faster the shear wave propagates [13].
The tip of the transducer probe was placed on the skin, be-
tween the ribs, at the level of the right lobe. Once the target area
has been located, acquisition was triggered by pressing a but-
ton. The measurement depth is between 25 and 65 mm below
the skin surface. In this study, at least ﬁve successful measure-
ments were made in each patient. The median value of all suc-
cessful acquisitions in each patient was recorded as the liver
elastic modulus.
The operator who performed the liver stiffness measure-
ment was unaware of neither the clinical nor the laboratory
data of the patients. Results are expressed in kilopascals (kPa).
The values used to correlate elastometry with METAVIR
scoring system are as follows: 0–2.9 kPa for F0, 3–5.9 kPa
for F1, 6–8.9 kPa for F2, 9–16.9 kPa for F3 and 17–75 kPa
for F4 [14].
Liver biopsy was done for 80 patients, ultrasonographically
guided. METAVIR scoring system was used to assess the necr-
oinﬂammatory grades of activity and stages of ﬁbrosis.
METAVIR scoring system is one of the few validated scor-
ing systems. This system assesses histological lesions in chronic
hepatitis C using two separate scores, one for the necroinﬂam-
matory grade and another for the stage of ﬁbrosis. These
scores are deﬁned as follows:
Stages of ﬁbrosis (F): F0: no ﬁbrosis; F1: portal ﬁbrosis
without septa; F2: portal ﬁbrosis with rare septa, F3: numer-
ous septa without cirrhosis; F4: cirrhosis.
Grades of activity (A): A0: no necroinﬂammatory activity;
A1: minimal activity, A2: moderate activity, A3: severe
activity.
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scoring system are lower than those of the widely used Knodell
scoring system. ForMETAVIR ﬁbrosis stage there is an almost
perfect concordance [14].
Exclusion criteria:
1. Patients with decompensated cirrhosis.
2. Patients with hepatocellular carcinoma.
3. Patients with diabetes mellitus.
4. Patients with HBV co-infection.
5. Prior or current antiviral therapies.
6. Current or past history of regular or excessive alcohol
consumption.
7. Other liver diseases such as alcoholic liver disease, non-
alcoholic fatty liver disease (NAFLD), drug-induced
hepatitis, other viral hepatitis, hereditary hemochroma-
tosis, Wilson’s disease, autoimmune hepatitis, primary
biliary cirrhosis, primary sclerosing cholangitis and a1
antitrypsin deﬁciency.
8. Current intravenous drug abuse.
9. HIV infection.
10. Obese patients (BMIP 30).
11. Patients refusing to be entitled in the study.
This study was approved by the local ethical committee of
Ain Shams University Hospitals and a written consent was ob-
tained from each individual before participation in the study.Table 1 Correlation between stages of ﬁbrosis and other
studied parameters.
Fibrosis score Mean ± SD F P
Age (years)
FS0, N= 10 39.3 ± 9.1 3.2 0.01
FS1, N= 29 41.3 ± 9.2
FS2, N= 56 37.3 ± 8.2
FS3, N= 29 43.6 ± 9.1
FS4, N= 14 44.0 ± 10.6
Body mass index (kg/m2)
FS0, N= 10 23.5 ± 1.3 4.2 0.003
FS1, N= 29 28.6 ± 4.9
FS2, N= 56 26.3 ± 3.6
FS3, N= 29 28.0 ± 4.1
FS4, N= 14 28.3 ± 3.5
ALT (IU/l)
FS 0, N= 10 39.0 ± 32.3 4.0 0.004
FS1, N= 29 82.6 ± 63.5
FS2, N= 56 50.9 ± 24.1
FS3, N= 29 62.0 ± 38.0
FS4, N= 14 74.3 ± 41.9
Albumin (g/dl)
FS0, N= 10 4.2 ± 0.2 3.1 0.01
FS1, N= 29 4.0 ± 0.3
FS2, N= 56 4.0 ± 0.2
FS3, N= 29 3.9 ± 0.3
FS4, N= 14 3.9 ± 0.3
Direct bilirubin (mg/dl)
FS0, N= 10 0.18 ± 0.2 1.4 0.2
FS1, N= 29 0.20 ± 0.1
FS2, N= 56 0.23 ± 0.2
FS3, N= 29 0.29 ± 0.2
FS4, N= 14 0.26 ± 0.22.1. Statistical methods
The data were collected, coded and entered to a personal com-
puter (P.C.) IBM compatible 2.6 GHz. The data was analyzed
with the program Statistical Package for Social Science (SPSS)
under Windows version 11.0.1. The following tests were used:
calculation of the mean value, Student’s t-test, one way analy-
sis of variance (ANOVA), and Chi-square test. The probability
of error (P) was expressed as following:
P-value > 0.05: non-signiﬁcant (NS).
P-value 6 0.05: signiﬁcant (S).
P-value < 0.01: highly signiﬁcant (HS).
3. Results
A total of 138 patients with chronic HCV (genotype 4) infec-
tion were enrolled in the study. Most patients were men
(78.3%), their mean age was 40.3 years and their mean BMI
was 27.2 kg/m2.
On correlating the stages of ﬁbrosis to other studied param-
eters, the following was found.
Signiﬁcant higher mean ALT levels were found among
patients with ﬁbrosis stages 1 and 4 as compared to other
stages of ﬁbrosis (P= 0.004) (Table 1).
Signiﬁcant higher mean age was found among patients with
ﬁbrosis stages 3 and 4 as compared to other stages of ﬁbrosis
(P= 0.01) (Table 1).
A signiﬁcant lower BMI was found among patients with
stage 0 ﬁbrosis as compared to other stages of ﬁbrosis
(P= 0.003) (Table 1).
Signiﬁcant lower mean albumin levels were found among
the cases with ﬁbrosis stages 3 and 4 as compared to other
stages of ﬁbrosis (P= 0.01) (Table 1).
A highly signiﬁcant higher percentage of cases with high le-
vel of HCV viremia was found among patients with ﬁbrosis
stage 3 as compared to other stages of ﬁbrosis (P= 0.000)
(Table 2).
On correlating the grades of histological activity (among
the 80 patients who underwent liver biopsy) to other studied
parameters, the only signiﬁcant correlation was found between
the grades of activity and the stages of ﬁbrosis (P= 0.000)
(Tables 3–5).
4. Discussion
While there are many studies regarding the correlation of liver
damage with serum HCV-RNA titer, ALT level, and HCV
genotypes, the conclusions are quite different [15–20]. The cur-
rent study investigated the correlation between serum HCV-
RNA titer, ALT level, and the severity of liver damage in
patients with chronic HCV (genotype 4) infection.
In general, chronic hepatitis C patients with elevated ALT
levels and high HCV-RNA titers in the sera are considered
to have active HCV replication in the liver and to be at risk
for continued liver injury. Also, the serum ALT level is recog-
nized as a marker reﬂecting the degree of the histological dam-
age and has served as a parameter for starting therapy or
judging response to antiviral treatment in chronic hepatitis C
Table 3 Correlation between grades of histological activity
and other studied parameters.
Grades of activity Mean ± SD F P
Age (years)
Grade 1, N= 21 37.7 ± 9.4 1.5 0.2
Grade 2, N= 36 38.0 ± 8.6
Grade 3, N= 20 40.1 ± 8.1
Grade 4, N= 3 48.3 ± 11.1
Body mass index (kg/m2)
Grade 1, N= 21 25.3 ± 3.2 1.1 0.3
Grade 2, N= 36 26.8 ± 4.0
Grade 3, N= 20 27.3 ± 3.7
Grade 4, N= 3 28.0 ± 4.2
ALT (IU/l)
Grade 1, N= 21 43.5 ± 33.7 2.4 0.07
Grade 2, N= 36 59.0 ± 44.1
Grade 3, N= 20 73.9 ± 33.9
Grade 4, N= 3 37.3 ± 17.9
Albumin (g/dl)
Grade 1, N= 21 4.2 ± 0.2 2.4 0.06
Grade 2, N= 36 4.0 ± 0.3
Grade 3, N= 20 4.0 ± 0.3
Grade 4, N= 3 3.8 ± 0.2
Direct bilirubin (mg/dl)
Grade 1, N= 21 0.14 ± 0.1 1.2 0.2
Grade 2, N= 36 0.19 ± 0.2
Grade 3, N= 20 0.19 ± 0.1
Grade 4, N= 3 0.33 ± 0.4
Table 2 Correlation between stages of ﬁbrosis and level of HCV viremia.
Low viremia Moderate viremia High viremia v2 P
No. % No. % No. %
FS0, N= 10 7 70.0 3 30.0 0 29.1 0.000
FS1, N= 29 10 34.5 12 41.4 7 24.1
FS2, N= 56 19 33.9 32 57.1 5 8.9
FS3, N= 29 10 34.5 8 27.6 11 37.9
FS4, N= 14 11 78.6 3 21.4 0
Table 4 Correlation between grades of histological activity
and level of HCV viremia.
Low
level
viremia
Moderate
viremia
High
viremia
v2 P
No. % No. % No. %
Grade 1, N= 21 14 66.7 5 23.8 2 9.5 0.1 0.7
Grade 2, N= 36 20 55.6 10 27.8 6 16.7
Grade 3, N= 20 13 65.0 0 7 35.0
Grade 4, N= 3 3 100.0 0 0
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the relationships among the degree of histological damage, ser-
um ALT level, HCV-RNA titers and HCV genotype. While
Zechini and colleagues found a correlation between serum
ALT level and liver damage [16], Puoti and colleagues argued
such a correlation [17].
The current study revealed an insigniﬁcant correlation be-
tween ALT level and the grades of necroinﬂammation
(P= 0.07). Strikingly, patients with stages 1 and 4 hepatic
ﬁbrosis had signiﬁcantly higher levels of ALT than patients
with other stages of hepatic ﬁbrosis (P= 0.004).
These ﬁndings are totally discordant to the ﬁndings of Liu
and colleagues [18] who found that the level of serum ALT was
not markedly related to the stages of liver ﬁbrosis but was
statistically linked with the grades of liver necroinﬂammatory
activity.
These conﬂicting results could be attributed to the differ-
ences in HCV genotypes and the ethnicity of the populationstudied. Also these ﬁndings suggest that serum ALT level
cannot serve as a parameter to assess liver damage in the pa-
tients with chronic hepatitis C virus infection. It is not easy to
explain the reason for the poor correlation between ALT
level and the severity of liver damage. In general, ALT is re-
leased by direct virus-related cytopathic activity and/or by an
immune-mediated process [18]. Some studies suggested that
the cellular immune response in patients of HCV infection
with persistent normal ALT levels is less activated than in pa-
tients with abnormal ALT levels [20,21], Also, Calabrese and
colleagues proposed that hepatocyte apoptosis has an impor-
tant role since chronic liver damage and hepatocyte cell loss
by apoptosis could occur in HCV-infected patients without
overt ALT level changes, explaining the progressive nature
of liver disease that was presented in patients with a normal
ALT level [22].
As for the relationship between serum HCV-RNA titer and
liver histological damage, studies have shown different and
conﬂicting results. Some showed no relationship [23–24], while
others revealed signiﬁcant correlations between serum HCV-
RNA titer and liver damage [25]. The current study showed
a highly signiﬁcant higher levels of HCV-RNA titer among
the patients with stage 3 hepatic ﬁbrosis (P= 0.000). In con-
trast, grades of activity were independent of serum HCV-
RNA titer (P= 0.7).
The mechanism of liver damage caused by HCV is not yet
fully understood and could be attributed to either direct cyto-
pathic damage by HCV or immune-mediated hepatic injury in-
duced by HCV [18].
The results of the current study further indicate that liver
damage is not caused by HCV directly, and immune-mediated
liver injury may be the major cause.
Patient’s age is a well known factor that is associated with
the responsiveness to Pegylated interferon a/ribavirin therapy
in chronic HCV infection. Generally, it is believed that youn-
ger individuals (usually < 40 years of age) respond better to
IFN-a treatment than older persons [26–27]. The obvious
Table 5 Correlation between grades of histological activity and stages of ﬁbrosis.
Fibrosis Activity v2 P
1 2 3 4
No. % No. % No. % No. %
FS0, N= 10 9 90.0 1 10.0
FS1, N= 21 8 38.1 10 47.6 3 14.3
FS2, N= 21 4 19.0 12 57.1 5 23.8 57.3 0.000
FS3, N= 17 11 64.7 6 35.3
FS4, N= 11 2 18.2 6 54.4 3 27.3
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advanced liver disease, such as ﬁbrosis and cirrhosis (them-
selves predictors of poor virological responses) [28].
Cross sectional studies have indicated that the age at
acquisition of HCV infection is positively associated with
the rate of ﬁbrosis progression [29]. Furthermore, the impor-
tance of considering age in a patient who is initiating therapy
for chronic HCV infection has been highlighted by a recent
study by Davis and coworkers [30] who developed a multico-
hort natural history model for predicting disease outcomes
and the beneﬁts of therapy in HCV-infected patients. Also,
Asselah et al. undertook a prospective cross sectional analysis
of 290 individuals with chronic hepatitis C infection. Higher
levels of ﬁbrosis were correlated with the age at infection
[31]. In accordance with these reports, the current study re-
vealed a signiﬁcant correlation between age and stage of
ﬁbrosis as patients with stages 3 and 4 hepatic ﬁbrosis had
signiﬁcantly higher mean age than patients with other stages
of ﬁbrosis (P= 0.01).
Chronic hepatitis C (CHC) can be considered not only as a
viral disease but also as a special type of metabolic disease [28].
Insulin resistance, obesity, and steatosis are associated with a
higher risk of ﬁbrosis progression in chronic HCV infection
[32–33]. Despite excluding obese patients, the current study re-
vealed a signiﬁcant correlation between BMI and stage of
ﬁbrosis. Patients with stage 0 hepatic ﬁbrosis had signiﬁcantly
lower mean BMI than patients with other stages (P= 0.003).
This result highlights the importance of metabolic factors in
ﬁbrosis progression in chronic HCV genotype 4 infection (even
in non obese patients).
Regarding the relation between grades of necroinﬂamma-
tion activity and stages of hepatic ﬁbrosis, the current study re-
vealed a highly signiﬁcant correlation between grades of
necroinﬂammatory activity and stages of ﬁbrosis (P= 0.00,
r= 0.663). This result conﬁrms other reports which found a
signiﬁcant correlation between higher levels of ﬁbrosis and
higher grades of hepatic necroinﬂammation [31–34]. Also,
McCaughan and George suggested that progressive inﬂamma-
tion may underlie the observed non-linear rates of ﬁbrosis pro-
gression in chronic HCV infected patients [34].
In Conclusion, neither serum HCV-RNA titer nor serum
ALT level can reﬂect the histological liver change accurately.
As a result, liver biopsy or other noninvasive procedures that
measure liver stiffness (transient elastography ‘‘Fibroscan’’) re-
main essential for accurate staging of liver ﬁbrosis in patients
with chronic HCV (genotype 4) infection.References
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